Avalo Therapeutics, Inc. Common Stock (AVTX) is a publicly traded Healthcare sector company. As of May 21, 2026, AVTX trades at $16.84 with a market cap of $849.46M and a P/E ratio of -2.79. AVTX moved +0.15% today. Year to date, AVTX is +1.62%; over the trailing twelve months it is +297.32%. Its 52-week range spans $3.39 to $24.27. Analyst consensus is strong buy with an average price target of $46.78. Rallies surfaces AVTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes AVTX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $16.84 |
| Market Cap | $849.46M |
| P/E Ratio | -2.79 |
| EPS | $-5.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $24.27 |
| 52-Week Low | $3.39 |
| Volume | 321 |
| Avg Volume | 0 |
| Revenue (TTM) | $59.00K |
| Net Income | $-78.26M |
| Gross Margin | 0.00% |
9 analysts cover AVTX: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $46.78.